AXLRx Book a callCommission

Rare Disease · United States · In-Market

US Pompe Disease Disease Landscape

GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population.

Assess this report View Sample Assessment Reviewed by Priyanka, Analyst Last updated July 2026
Market United States United Kingdom GCC (Gulf) Stage

Key takeaways

  • 70–80% of US Pompe patients have the late-onset form (LOPD) · AMDA / NORD
  • years typical delay from first LOPD symptom to GAA-confirmed diagnosis; often mistaken for limb-girdle muscular dystrophy · Kishnani Genet Med 2006 (PMID 16702877)
  • GAA acid alpha-glucosidase — the deficient lysosomal enzyme; dried-blood-spot assay is the definitive test · Kishnani Genet Med 2006 (PMID 16702877)

Pompe disease is defined by acid alpha-glucosidase deficiency — and late-onset disease, ~70–80% of US patients, is where diagnostic delay and respiratory decline shape commercial strategy.

Pompe disease is an autosomal-recessive metabolic myopathy caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to glycogen accumulation in skeletal, respiratory, and (in infants) cardiac muscle. The US Pompe population is estimated at roughly 5,000–10,000 patients. Late-onset Pompe disease (LOPD), defined by residual GAA activity above about 1%, accounts for an estimated 70–80% of patients and spans a wide phenotype, from enzyme-test-detected and near-asymptomatic to wheelchair- and ventilator-dependent respiratory failure. Infantile-onset Pompe (IOPD), with near-absent GAA activity, presents in the first months of life with hypertrophic cardiomyopathy and profound hypotonia, and was historically fatal within the first year without treatment.

Two features define the LOPD landscape. First, diagnosis is slow: patients are frequently worked up for limb-girdle muscular dystrophy or idiopathic myopathy for years before a dried-blood-spot GAA enzyme assay confirms the diagnosis. Second, respiratory decline, not limb weakness, is the clinical clock; in the Pompe natural-history literature disease severity tracks disease duration, so earlier-onset patients reach wheelchair and ventilator dependence sooner. Newborn screening for Pompe is expanding the pre-symptomatic identified pool and reshaping when and where enzyme replacement therapy begins.

Late-onset versus infantile-onset Pompe disease — clinical and diagnostic comparison

DISEASE SPECTRUM
ParameterLate-Onset Pompe (LOPD)Infantile-Onset Pompe (IOPD)
Share of US Pompe~70–80% of patients~20–30% of patients
Residual GAA activityPartial (>~1%)Near-absent (<1%)
Typical onsetChildhood to late adulthoodFirst months of life
Cardinal featuresProximal limb-girdle weakness; progressive respiratory / diaphragmatic declineHypertrophic cardiomyopathy; profound hypotonia; respiratory failure
Diagnostic testDried-blood-spot GAA assay → confirmatory GAA gene sequencingSame; frequently flagged first by newborn screening
Newborn screeningShifts detection pre-symptomatic; surveillance until symptom onsetEnables early ERT before irreversible cardiac damage
Natural historyProgressive; severity tracks disease duration; ventilator/wheelchair dependence over timeRapid; historically fatal within the first year untreated

Sources: Kishnani PS et al. Genet Med 2006 (PMID 16702877); Hagemans ML et al. Neurology 2005 (PMID 15985590); van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906); AMDA / NORD Pompe epidemiology.

What this assessment answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. What is the size and phenotype composition of the US late-onset Pompe population? • US Pompe prevalence estimate • the LOPD versus IOPD split by residual GAA activity • the phenotype spectrum from enzyme-test-detected to ventilator-dependent
  2. Where does the diagnostic delay in late-onset Pompe come from, and how is it being closed? • The limb-girdle-muscular-dystrophy misdiagnosis pathway • the dried-blood-spot GAA assay as the definitive test • newborn screening's role in pre-symptomatic identification
  3. What is the natural history of respiratory and motor decline in LOPD, and why does it drive treatment timing? • Respiratory decline as the clinical clock • severity tracking disease duration in the Pompe natural-history literature • the functional measures (FVC and 6-minute walk) that gate treatment
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · Disease Biology & GAA Enzyme Deficiency 4 pp
    • Why GAA enzyme deficiency below roughly 1% residual activity separates infantile-onset from late-onset Pompe disease.
    • How glycogen accumulation in skeletal, respiratory, and cardiac muscle drives the disease's two distinct phenotypes.
  2. 2 · US Epidemiology & the LOPD vs IOPD Split 5 pp
    • Why LOPD accounts for 70-80% of the estimated 5,000-10,000 US Pompe patients, per AMDA and NORD.
    • How residual GAA activity above 1% defines LOPD versus the near-absent activity that marks IOPD.
  3. 3 · Diagnostic Pathway & Delay Analysis 4 pp
    • Why LOPD patients are frequently misdiagnosed with limb-girdle muscular dystrophy for years before confirmation.
    • How the dried-blood-spot GAA assay, followed by gene sequencing, closes the diagnostic gap identified by Kishnani 2006.
  4. 4 · Respiratory & Motor Decline Trajectory 5 pp
    • Why respiratory decline, not limb weakness, is the clinical clock that determines treatment timing in LOPD.
    • How disease severity tracking disease duration means earlier-onset patients reach ventilator dependence sooner.
  5. 5 · Newborn Screening & the Pre-Symptomatic Pool 4 pp
    • Why newborn screening is expanding the pre-symptomatic identified pool and reshaping when enzyme replacement therapy begins.
    • How early detection in IOPD enables enzyme replacement therapy before irreversible cardiac damage occurs.
  6. 6 · Phenotype Spectrum & Unmet Need 4 pp
    • Why LOPD spans a spectrum from enzyme-test-detected, near-asymptomatic patients to wheelchair- and ventilator-dependent cases.
    • How IOPD's hypertrophic cardiomyopathy and profound hypotonia within months of birth contrast with LOPD's decades-long course.

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom assessment delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
Pompe Disease Landscape — US Complete Edition
20–25 page disease landscape assessment: Pompe epidemiology, GAA biology, LOPD vs IOPD phenotypes, diagnostic pathway, and respiratory-decline trajectory.
XLS
Excel Model
Patient Flow Model — Excel
Pompe patient funnel: US prevalence, LOPD/IOPD split, diagnosis rate, symptomatic and treatment-eligible population sizing.
PPT
PowerPoint
Executive Readout — PowerPoint
12–15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.

Get Started

Commission this assessment

AXLRx Pompe Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US late-onset Pompe population. Custom assessment in 72 hours.

  1. 1. Submit your requestSpecify indication, geography, and epidemiological focus.
  2. 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
  3. 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
Assess this report View sample assessments

How AXLRx builds this assessment

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Pompe disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and registry data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.

Key sources: Kishnani PS et al. Genet Med 2006 (PMID 16702877); Hagemans ML et al. Neurology 2005 (PMID 15985590); van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906); AMDA and NORD Pompe disease epidemiology references.

  • Pompe diagnosis pathway and phenotype classification verified against Kishnani PS et al. Genet Med 2006 (PMID 16702877)
  • LOPD natural history (severity tracking disease duration) verified against Hagemans ML et al. Neurology 2005 (PMID 15985590)
  • Disease biology and ERT context verified against van der Ploeg AT & Reuser AJJ. Lancet 2008 (PMID 18929906)
  • US prevalence and the LOPD/IOPD split triangulated against AMDA and NORD Pompe disease references

Frequently asked questions

Disease What is the difference between late-onset and infantile-onset Pompe disease?

Both are caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), but they differ by residual enzyme activity. Infantile-onset Pompe (IOPD) has near-absent GAA activity and presents in the first months of life with hypertrophic cardiomyopathy and profound hypotonia; it was historically fatal within the first year untreated. Late-onset Pompe (LOPD) has residual GAA activity above roughly 1%, accounts for an estimated 70–80% of US patients, and presents later with proximal limb-girdle weakness and progressive respiratory decline across a wide phenotype.

Diagnosis Why is late-onset Pompe disease so often diagnosed late?

LOPD mimics more common neuromuscular conditions — patients are frequently worked up for limb-girdle muscular dystrophy or idiopathic myopathy for years before Pompe is considered. The dried-blood-spot GAA enzyme assay is a rapid, definitive test that can confirm the diagnosis, and newborn screening is expanding pre-symptomatic identification, but awareness among generalist neurologists remains the rate-limiting step.

Deliverables What formats are included with every assessment?

Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.